Resistance Exercise and Creatine in Colorectal Cancer

Summary

skeletal muscle mass and function, is prevalent in up to 60% of colorectal cancer patients. This condition arises from a combination of factors such as aging, inactivity, treatment side effects, malnutrition, tumor burden, and inflammation. Given this complexity, singular interventions may not be sufficient to address sarcopenia in this group. Creatine monohydrate, a compound vital for energy during exercise, has been extensively researched and proven safe and effective across various demographics, including older adults and clinical populations. Studies show that creatine enhances benefits from resistance training, indicating potential to counter muscle mass and function decline post-cancer treatment. This study aims to assess the feasibilty of combining creatine supplementation with resistance training versus resistance training alone in sarcopenic colorectal cancer survivors. A randomized controlled pilot trial will compare a 10-week program of resistance exercise plus creatine (EXSUPP) with resistance exercise alone (EXPLA), each with 20 participants.

Eligibility

Inclusion Criteria:

* . Individuals ≥12 months post treatment for colorectal cancer
* \>18 years

Exclusion Criteria:

1. are receiving active treatment for their cancer;
2. have a any contraindication to exercise participation;
3. have been participating in structured resistance exercise 2 or more times per week for the past 6 months;
4. are currently taking supplements containing creatine for 4 weeks prior to the start of the RCT, or
5. are receiving medications that might alter body composition (metformin, corticosteroids etc.).

Conditions2

Locations1 site

Browse More Trials